Although targeted therapy is usually the first-line treatment for advanced renal cell carcinoma (RCC), some patients can experience drug resistance. Cancer stem cells are tumour-initiating cells that play a vital role in drug resistance, metastasis and cancer relapse, while galectins (Gal) participate in tumour progression and drug resistance. However, the exact role of galectins in RCC stemness is yet unknown. In this study, we grew a subpopulation of RCC cells as tumour spheres with higher levels of stemness-related genes, such as Oct4, Sox2 and Nanog. Among the Gal family, Gal-3 in particular was highly expressed in RCC tumour spheres. To further investigate Gal-3's role in the stemness of RCC, lentivirus-mediated knockdown and overexpression of Gal-3 in RCC cells were used to examine both in vitro and in vivo tumorigenicity. We further assessed Gal-3 expression in RCC tissue microarray using immunohistochemistry. Upon suppressing Gal-3 in parental RCC cells, invasion, colony formation, sphere-forming ability, drug resistance and stemness-related gene expression were all significantly decreased. Furthermore, CXCL6, CXCL7 and CXCR2
cell RCC (ccRCC), its overall efficacy rate is restricted by its toxicity. Molecular targeting drugs, including tyrosine kinase and mTOR inhibitors, have been approved for treating advanced RCC. 1, 2 Nevertheless, long-lasting treatment responses cannot be achieved, and the overall survival rate is still poor due to drug resistance.
Cancer stem cells (CSCs) may contribute to drug resistance in human solid tumours. 3, 4 The frequency of functionally defined CSCs varies among different patients. With self-renewal as one of their hallmarks, CSCs can initiate tumour formation and metastasis. Furthermore, CSCs can be identified by in vitro sphere-forming assays and common cell surface markers, especially CD133 and CD44.
CSCs can express ATP-binding cassette (ABC) transporters to become more resistant to chemotherapy compared to the bulk of a tumour cell mass. 3, 4 The tumour microenvironment supports cancer progression and CSC formation through growth factors, cytokines and chemokines. For example, within the tumour microenvironment, endothelial cells produce angiocrine factors and myofibroblasts secrete the stem cell factor, CXCL12 and Wnt to modulate the stemness of CSCs. 5 Another critical component of the tumour microenvironment, galectin can control immune surveillance and aid tumour metastasis. 6 Galectins (Gals) are galactoside-binding lectins that contain conserved carbohydrate-recognition domains (CRDs) to bind β-galactose.
According to their structural features, galectins are classified into the following three categories: prototype, chimera type and tandemrepeat type. The chimera galectin type has only one member, 7 whose expression is required for initiating the transformed phenotype of tumours by interacting with oncogenic Ras. 8 The Gal-3-RAS interaction promotes the RAS anchorage to the plasma membrane, which results in the constitutive activation of phosphatidylinositol 3-kinase and Raf-1. 9 The tumorigenic potential of Gal-3 may also function through binding with β-catenin or transcriptional factors to increase the expressions of cyclin D and c-MYC and augment cell cycle progression. 10 Furthermore, intracellular Gal-3 inhibits cell death induced by cisplatin and paclitaxel, thus contributing to cancer cells' drug resistance and CSC formation. 11, 12 Extracellular Gal-3 has in vitro angiogenic activity by inducing the migration of endothelial cells. 13 Increased protein levels of Gal-3 are correlated with the poor survival of various cancers, including leukaemia, lymphomas, breast cancer and thyroid cancer. 6 Gal-3 was overexpressed in RCC patients with distant metastasis. 14 While chemokines and their receptors influence the initiation and progression of tumours in the tumour microenvironment, their role in the Gal-3-promoted CSC formation and drug resistance of RCC remains unclear. 5 In this study, we found that Gal-3 was highly expressed in the CSCs of 
CXCR2 by lentivirus-mediated system
Lentivirus-mediated silencing and overexpression of Gal-3 and CXCR2 of the RCC cells were performed as described in a previous study. 15 We obtained pLKO.1 plasmid containing shRNA targeting human Gal-3 (shGal-3#1, Clone ID TRCN0000029305;
shGal-3#2, Clone ID TRCN0000029307) and CXCR2 (shCXCR2, Clone ID TRCN0000009138) from the National RNAi Core Facility (Academia Sinica, Taipei, Taiwan). Full-length DNA encoding Gal-3
and CXCR2 genes were amplified using RT-PCR and cloned to pLAS2w. The primer sequences for cloning the full length of Gal-3
and CXCR2 are listed in Table S1 . To knockdown Gal-3 in RCC spheres, A-498-derived primary tumour spheres were dissociated into single cells, re-seeded in a 10% FBS-RPMI medium, infected with shGal-3 or shLuc lentivirus, and then cultured to form secondary spheres (2S).
| RT-qPCR
RT-qPCR was performed as described in a previous study. 15 The specific primers used in the RT-qPCR are presented in Table S2 .
| Western blotting
Total proteins were extracted using the RIPA Lysis buffer (Millipore, 
| Cell migration and invasion assays
We evaluated tumour cell migration and invasion assays using tran- 
| Tissue microarray (TMA) and immunohistochemistry (IHC)
We purchased tissue microarray slides from Biomax (US Biomax Inc., Rockville, MD) and performed IHC as described in a previous study. 15 TMA slides were incubated with the Gal-3 or CXCR2
(R&D system, Minneapolis, MN) primary antibody. The final value was the sum of the percentage of the stained area and the intensity of the stained cells. The detailed clinicopathologic characteristics of the patients included in the TMA are listed in Table S3 .
| Statistical analysis
Data are expressed as the mean ± SD. Differences between two groups were determined using Student's t test. We adopted the SurvExpress 16 web-based tool to analyse the gene expression of Gal-3
and CXCR2 in ccRCC (accession no. KIRC-TCGA). Survival durations were analysed using the Kaplan-Meier method and compared in the patient groups with the log-rank test. Using Cox survival analysis, we classified a population of ccRCC patients into high-risk and low-risk groups in accordance with their prognostic index. Statistical significance was set at P < 0.05.
| RESULTS

| Enrichment of renal CSCs
To determine whether cultured human RCC cell lines contained a population of CSCs, RCC cells were cultured in a defined serumfree selection tumour sphere medium for a few days. The morphology of the RCC cell spheres is shown in Figure 1A . We observed only 9% sphere formation in A-498, 7% in Caki-1 and 11% in ACHN cells ( Figure 1B ). The stemness-associated genes were analysed using RT-qPCR, and the results showed that the mRNA levels of Nanog, Sox2, Oct4, CD44, CD133, ABCB1, ABCC1, ABCG2 and Notch1 were significantly increased in RCC tumour spheres compared with parental cells ( Figure 1C ). Furthermore, we adopted Western blotting to confirm the protein levels of Nanog, Sox2 and Oct4 in three RCC tumour spheres (Figure 1D ).
| Galectin-3 was highly expressed in the tumour spheres of RCC cells
Galectins have been reported to promote cancer cells' chemoresistance and CSC formation. 12,17 Therefore, we analysed the galectin levels in renal CSCs using RT-qPCR. Regarding the galectin family, the expression of Gal-2, Gal-3, Gal-4 and Gal-7 was significantly 
| Galectin-3 maintained the stemness properties of renal CSCs
To further examine the role of Gal-3 in maintaining CSCs, we infected A-498 primary tumour spheres with shGal-3 lentivirus and then cultured them to form secondary spheres. First, we used Western blot to confirm galectin-3 knockdown in secondary spheres (Figure 3A) . Furthermore, silencing Gal-3 significantly reduced the sphere formation ( Figure 3B ), anchorage-independent growth (Figure 3C ), migration and invasion ( Figure 3D ) ability of the secondary sphere cells. Therefore, we also observed Gal-3 to participate in the maintenance of the stemness features of renal CSCs.
| Down-regulation of chemokine/cytokine expression in Gal-3-knockdown RCC tumour spheres
To study the molecular mechanism of Gal-3 in the CSCs, we analysed chemokine and chemokine receptor levels using RT-qPCR. As shown in Figure 4A , the expressions of several chemokines were reduced in both clones of the shGal-3-infected renal CSCs, including CXCL5, CXCL6, CXCL7 and CXCL9. The chemokine receptors CXCR2 and CXCR5 were also significantly down-regulated in the Gal-3 silenced CSCs. As CXCR2 and its ligands (CXCL6 and CXCL7)
were simultaneously inhibited in shGal-3 CSCs, we focused on the Primary (1°sphere) and secondary sphere (2°sphere) formation were analysed in the shLuc-and shGal-3-infected A-498 cells. Colony-forming (C), stemness-related gene expression levels (D), and invasiveness and migration (E) abilities were examined in the spheres of shLuc-and shGal-3-infected A-498 cells. *P < 0.05, **P < 0.01, ***P < 0.001. (F) The drug sensitivities of shLuc-and shGal-3-infected A-498 cell spheres were measured using sunitinib and sorafenib treatment.
# P < 0.05: shLuc (S) compared with shLuc; *P < 0.05: shGal-3 (S) compared with shLuc (S). The reported results are representative of three independent experiments (9.9%), the sphere cells expressed more CXCR2 (56%), and Gal-3 silencing decreased CXCR2 expression in the CSCs (26.9%).
| Suppression of CXCR2 led to decreased sphere-forming ability in RCC cells
We silenced CXCR2 in parental A-498 cells to investigate the role of CXCR2 in CSC formation. Compared to cells infected with the control virus expressing shLuc, cells infected with the shCXCR2 virus expressed lower levels of this particular chemokine receptor (Figure 4C) . Furthermore, sphere-forming ability was significantly downregulated by 50%-60% in the shCXCR2-infected RCC cells ( Figure 4D ).
| Overexpression of CXCR2 in shGal-3-infected RCC cells restored cell motility, colony formation and self-renewal capacity
To explore the role of CXCR2 in the formation of Gal-3-mediated CSCs, we infected Gal-3 knockdown (shGal-3) A-498 cells with lentivirus carrying the CXCR2 gene (pLAS2w/CXCR2). Compared to cells infected with the shLuc control virus, Gal-3 silencing significantly decreased the Nanog and Sox2 expression ( Figure 5A ), sphere formation ( Figure 5B ), anchorage-independent growth ( Figure 5C) and motility ( Figure 5D ) of RCC sphere cells. In contrast, CXCR2 overexpression significantly restored the expression of the Nanog and Sox2 expression ( Figure 5A ), sphere formation ( Figure 5B ), colony formation ( Figure 5C ) and motility ( Figure 5D ) of shGal-3 RCC sphere cells.
| Overexpression of galectin-3 in RCC cells promoted sphere-forming capacity and in vitro and in vivo tumorigenicity
We used lentivirus-mediated Gal The reported results are representative of three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001 RCC sphere cells generated tumour formation in three of four mice (data not shown). Furthermore, tumours generated by the Gal-3-overexpressed RCC spheres were larger than the RCC spherederived tumours ( Figure 6F ). These results suggest that Gal-3 overexpression in RCC sphere cells promote in vivo tumour growth.
| Galectin-3 expression correlated with CXCR2, tumour progression and prognosis in RCC tissues
To investigate the expression of Gal-3 and CXCR2 in human RCC tissues, we performed immunohistochemistry staining on tissue microarrays that contained samples from 75 patients with ccRCC.
We observed higher Gal-3 expression in the advanced stages (III+IV) and grade (poorly differentiated) RCC tissues ( Figure 7A and B).
CXCR2 expression was significantly correlated with tumour differentiation ( Figure 7C ) but not RCC stage (data not shown). Furthermore, Gal-3 expression was significantly higher in the CXCR2 high expression group than in the low expression group ( Figure 7D ). To further study the correlation between the expression levels of Gal-3/CXCR2
and patient prognosis, we used the online tool SurvExpress 16 to analyse 415 patients with various stages of ccRCC. Using Cox survival analysis, we found that patients with higher co-expressions of Gal-3 and CXCR2 had a significantly worse survival rate ( Figure 7E) and that Gal-3 expression correlated with CXCR2 expression, tumour progression and prognosis in RCC.
| DISCUSSION
The overexpression of Gal-3 is associated with the increased invasiveness of many kinds of tumours. Higher levels of Gal-3 are found in the sera of cancer patients with metastasis. 18 Gal-3 promotes cancer progression through intra-and extra-cellular mechanisms in the tumour microenvironment. Intracellular Gal-3 interacts with RAS and β-catenin to enhance cell transformation and proliferation. [8] [9] [10] Furthermore, Gal-3 augments tumour stem cell property and drug resistance through its interaction with β-catenin. 12 Several chemokine and chemokine receptor genes, such as CXCR4, CXCR7 and CCL5, 19, 20 are the downstream genes of β-catenin. In this study, we found that Gal-3 overexpression may promote CXCR2 to augment the stemness property of RCC. In our previous study, cancer spheres secreted higher levels of Gal-3, while Gal-3 knockdown reduced secretion levels. Recombinant Gal-3 promotes cancer sphere formation. 12 Furthermore, previous studies have demonstrated Gal-3 to interact with epidermal growth factor receptor (EGFR) and transforming growth factor-β receptor (TGFβR). 9 Therefore, extracellular Gal-3 may also stimulate sphere formation in collaboration with EGF or bFGF signalling in the tumour sphere medium.
Existing evidence indicates that drug resistance regulation by
Gal-3 may result from intracellular effects on the apoptotic pathways. 11 The anti-apoptotic mechanisms of Gal-3 include: (1) the phosphorylation status of Gal-3, 21 (2) the Gal-3 translocation from the nucleus to the cytoplasm, 22 (3) the regulation of mitochondrial membrane potential, 23 (4) the modulation of survival signalling pathway, 24 and (5) the regulation of the caspase pathway. 25 Furthermore, Gal-3 plays a crucial role in regulating the Wnt/β-catenin signalling pathway. The best evidence so far of the importance of the Wnt pathway to CSCs biology has been reported in myeloid leukaemia, but its contribution has also been reported in the maintenance of the CSCs of melanoma, breast, colon, and lung cancers. 40 Therefore, CXCR2 and its ligands are thought to serve a protective function in the early stages of tumorigenesis, thus complicating the role of CXCR2 in cancer formation and progression.
In the plasma of RCC patients, CXCR2 ligands CXCL1, CXCL3, CXCL5 and CXCL8 are elevated chemokines. 42 Furthermore, CXCL7
is a prognostic factor for the overall survival of RCC. CXCL7 promotes RCC cell proliferation both in vitro and in vivo, and a CXCL7/ CXCR2 blockade by antibody or inhibitor reduces tumour growth in mice. 34 Altogether, these findings indicate the importance of CXCR2
in the progression and targeting therapy of RCC. 43 In summary, we have demonstrated that highly expressed Gal-3 can up-regulate CXCR2 to augment the stemness property of RCC.
Gal-3 and CXCR2 expressions were correlated with RCC tumour progression, and Gal-3 expression correlated with CXCR2 expression in RCC tissues. As we found that higher co-expressions of Gal-3 and Patients were divided into two groups (low and high) based on whether their CXCR2 levels were below or above the median value. Galectin-3 expression levels were compared between low and high levels of CXCR2 in ccRCC tissues. *P < 0.05. (E) Kaplan-Meier curves according to galectin-3 and CXCR2 expression levels in patients with ccRCC were conducted using SurvExpress web-based analysis. Censoring samples are shown as "+" marks. Data set, concordance index (CI) and P-value of the log-rank test are shown. Red and green curves denoted high-risk (high expression levels) and low-risk (low expression levels) groups, respectively
